1. Educational experience
(1) 2010.09-2016.06: Ph.D. in Pharmacology, School of Basic Medicine, Peking University Department of Medicine
(2) 2006.09-2010.06: Bachelor's degree in Pharmacy, School of Pharmacy, Nanjing Medical University
2. Work experience
(1) 2016.07- present, School of Pharmacy, China Pharmaceutical University
(1) the pathological mechanism and drug targets of neurodegenerative diseases
(2) the pathological mechanisms and drug targets of cardiovascular diseases
(3) the pathological mechanism and drug target of diabetes
(1) the National Natural Science Foundation of China (81703520)
(2) the Key Research and Development Program of Ningxia (2019BFG02017)
1.He, L.; Sun, Y., The potential role of Keap1-Nrf2 pathway in the pathogenesis of Alzheimer's disease, type 2 diabetes, and type 2 diabetes-related Alzheimer's disease. Metab Brain Dis 2021, 36 (7), 1469-1479.
2.Sun, Y.; Huang, J.; Chen, Y.; Shang, H.; Zhang, W.; Yu, J.; He L.; Xing, C.; Zhuang, C., Direct inhibition of Keap1-Nrf2 Protein-Protein interaction as a potential therapeutic strategy for Alzheimer's disease. Bioorg Chem. 2020 Oct;103:104172.
3.He, J.; Sun, Y.; Jia, Y.; Geng, X.; Chen, R.; Zhou, H.; Yang, B., Ganoderma triterpenes Protect Against Hyperhomocysteinemia Induced Endothelial-Mesenchymal Transition via TGF-beta Signaling Inhibition. Front Physiol 2019, 10, 192.
4.Zang, X.; Cheng, Z. Y.; Sun, Y.; Hua, N.; Zhu, L. H.; He, L., The ameliorative effects and underlying mechanisms of dopamine D1-like receptor agonist SKF38393 on Abeta1-42-induced cognitive impairment. Prog Neuropsychopharmacol Biol Psychiatry 2018, 81, 250-261.
